Literature DB >> 9819313

Benefits and risks of inhaled glucocorticoids in children with persistent asthma.

F E Simons1.   

Abstract

In children, an inhaled glucocorticoid is currently the medication of choice for the long-term control of persistent asthma. Inhaled glucocorticoids are significantly more effective than nonsteroidal medications on all outcome measures of asthma treatment. They reduce the frequency of symptoms and of acute asthma exacerbations, decrease the need for "rescue" medications, improve airway patency, and reduce airway hyperresponsiveness. These considerable long-term benefits are worth the minimal risks of clinically significant local or systemic adverse effects. An inhaled glucocorticoid should be used in the lowest dose that prevents symptoms and eliminates the need for supplemental courses of ingested glucocorticoids. Pulmonary function and height velocity of children receiving an inhaled glucocorticoid should be monitored at regular intervals.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9819313     DOI: 10.1016/s0091-6749(98)70035-1

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  6 in total

Review 1.  Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.

Authors:  L P Boulet; A Becker; D Bérubé; R Beveridge; P Ernst
Journal:  CMAJ       Date:  1999-11-30       Impact factor: 8.262

Review 2.  Once-daily inhaled corticosteroids in children with asthma: dry powder inhalers.

Authors:  C Möller
Journal:  Drugs       Date:  1999       Impact factor: 9.546

3.  Glucocorticoids modulate TGF-beta production by human fetal lung fibroblasts.

Authors:  Fu-Qiang Wen; Tadashi Kohyama; C Magnus Sköld; Yun Kiu Zhu; Xiangde Liu; Debra J Romberger; Julie Stoner; Stephen I Rennard
Journal:  Inflammation       Date:  2003-02       Impact factor: 4.092

4.  Glucocorticoids modulate TGF-beta production.

Authors:  Fu-Qiang Wen; Tadashi Kohyama; C Magnus Sköld; Yun Kiu Zhu; Xiangde Liu; Debra J Romberger; Julie Stoner; Stephen I Rennard
Journal:  Inflammation       Date:  2002-12       Impact factor: 4.092

5.  Single Nucleotide and Copy-Number Variants in IL4 and IL13 Are Not Associated with Asthma Susceptibility or Inflammatory Markers: A Case-Control Study in a Mexican-Mestizo Population.

Authors:  Enrique Ambrocio-Ortiz; Gustavo Galicia-Negrete; Gloria Pérez-Rubio; Areli J Escobar-Morales; Edgar Abarca-Rojano; Alma D Del Angel-Pablo; Manuel D J Castillejos-López; Ramcés Falfán-Valencia
Journal:  Diagnostics (Basel)       Date:  2020-04-30

Review 6.  Asthma diagnosis: into the fourth dimension.

Authors:  Ran Wang; Clare S Murray; Stephen J Fowler; Angela Simpson; Hannah Jane Durrington
Journal:  Thorax       Date:  2021-01-27       Impact factor: 9.139

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.